CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS
Although antibodies targeting Ro52 protein/TRIM21 are commonly detected in systemic autoimmune rheumatic disorders (SARDs), their clinical significance and pathobiologic role remains incompletely understood. Objectives. We aimed to define clinical relevance and immunological associations of anti-Ro...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2017-09-01
|
| Series: | Romanian Journal of Rheumatology |
| Subjects: | |
| Online Access: | https://rjr.com.ro/articles/2017.3/RJR_2017_3_Art-04.pdf |
| _version_ | 1828943623602831360 |
|---|---|
| author | Cristina Pomirleanu Raluca Paiu Georgiana Strugariu Luiza Petrariu Codrina Ancuta |
| author_facet | Cristina Pomirleanu Raluca Paiu Georgiana Strugariu Luiza Petrariu Codrina Ancuta |
| author_sort | Cristina Pomirleanu |
| collection | DOAJ |
| description | Although antibodies targeting Ro52 protein/TRIM21 are commonly detected in systemic autoimmune rheumatic disorders (SARDs), their clinical significance and pathobiologic role remains incompletely understood.
Objectives. We aimed to define clinical relevance and immunological associations of anti-Ro52/TRIM21 positivity in a cohort of patients with SARDs.
Methods. We retrospectively reviewed medical records of 97 consecutive SARDs who attended at least once our Rheumatology Department between March 2016 and June 2017. Clinical manifestations, rheumatoid factor (RF) (Latex and Waalter-Rose tests), antinuclear antibodies (ANA>1:100, immunofluorescence assays) as well
as detailed ANA profile (nRNP/Sm, Sm, SS-A/Ro, Ro52/TRIM21, SS-B/La, Scl-70, PM/Scl, Jo-1, CENP-B, PCNA, dsDNA, nucleosome, histone, P-ribosomal protein, AMA-M2, DFS70) (line immunoblot assay) were systematically evaluated.
Statistical analysis was performed in SPSS19.0, assuming significance for p<0.05; the chi-squared test was applied to determine the association between anti-Ro52/TRIM21 status and clinical manifestations of SARDs.
Results. Only 27 patients (23.7%) had anti-Ro52/TRIM21 positive disease and were further analyzed. Isolated anti-Ro52/TRIM21 were detected in 7/27 (25.9 %) cases, while the majority had dual anti-Ro52/TRIM21 positivity and anti-Ro (n=7/20; 35%), anti-dsDNA (n=3/20, 15%), anti-Jo1 (n=3/20, 15%), anti-centromere B (n=2/20; 10%), anti-Scl70 (n=2/20; 10%), anti-RNP/Sm (n=2/20, 10%), anti-Pm/Scl (n=1/20, 5%), and RF (n=13; 65%).
Patients were classified as Sjögren’s syndrome (n=7/27, 25.9%), myositis (n=3/27, 11.1%), systemic lupus erythematosus (n=3/27, 11.1%), systemic sclerosis (n=4/27,15.2%), mixed (n=3/27, 11.1%) or undifferentiated connective tissue disease (n=7/27, 25.9%).
More than half of anti-Ro52/TRIM21 positive patients presented with interstitial lung fibrosis (18/27, 66.6%), insolated (33.3%) or in association with anti-Jo1 (33.3%).
Conclusions. Anti-Ro52/TRIM21 antibodies should be systematically evaluated in patients with SARDs, as antiRo52 positivity (either isolated or in combination with different other ANA specificities) may be associated with definite clinical features.
Anti-Ro52/TRIM21 may be useful in identifying a subgroup of patients at risk for developing certain symptoms (particularly interstitial lung disease) of SARDs, with specific therapeutic outcomes. |
| first_indexed | 2024-12-14T04:18:35Z |
| format | Article |
| id | doaj.art-0790752467ba45eb8b40e694514717b6 |
| institution | Directory Open Access Journal |
| issn | 1843-0791 2069-6086 |
| language | English |
| last_indexed | 2024-12-14T04:18:35Z |
| publishDate | 2017-09-01 |
| publisher | Amaltea Medical Publishing House |
| record_format | Article |
| series | Romanian Journal of Rheumatology |
| spelling | doaj.art-0790752467ba45eb8b40e694514717b62022-12-21T23:17:26ZengAmaltea Medical Publishing HouseRomanian Journal of Rheumatology1843-07912069-60862017-09-0126312913410.37897/RJR.2017.3.4CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTSCristina Pomirleanu0Raluca Paiu1Georgiana Strugariu2Luiza Petrariu3Codrina Ancuta4Grigore T. Popa University of Medicine and Pharmacy, Iasi; Rheumatology 2 Department, Clinical Rehabilitation Hospital, IasiRheumatology 2 Department, Clinical Rehabilitation Hospital, IasiRheumatology 2 Department, Clinical Rehabilitation Hospital, IasiRheumatology 2 Department, Clinical Rehabilitation Hospital, IasiGrigore T. Popa University of Medicine and Pharmacy, Iasi; Rheumatology 2 Department, Clinical Rehabilitation Hospital, IasiAlthough antibodies targeting Ro52 protein/TRIM21 are commonly detected in systemic autoimmune rheumatic disorders (SARDs), their clinical significance and pathobiologic role remains incompletely understood. Objectives. We aimed to define clinical relevance and immunological associations of anti-Ro52/TRIM21 positivity in a cohort of patients with SARDs. Methods. We retrospectively reviewed medical records of 97 consecutive SARDs who attended at least once our Rheumatology Department between March 2016 and June 2017. Clinical manifestations, rheumatoid factor (RF) (Latex and Waalter-Rose tests), antinuclear antibodies (ANA>1:100, immunofluorescence assays) as well as detailed ANA profile (nRNP/Sm, Sm, SS-A/Ro, Ro52/TRIM21, SS-B/La, Scl-70, PM/Scl, Jo-1, CENP-B, PCNA, dsDNA, nucleosome, histone, P-ribosomal protein, AMA-M2, DFS70) (line immunoblot assay) were systematically evaluated. Statistical analysis was performed in SPSS19.0, assuming significance for p<0.05; the chi-squared test was applied to determine the association between anti-Ro52/TRIM21 status and clinical manifestations of SARDs. Results. Only 27 patients (23.7%) had anti-Ro52/TRIM21 positive disease and were further analyzed. Isolated anti-Ro52/TRIM21 were detected in 7/27 (25.9 %) cases, while the majority had dual anti-Ro52/TRIM21 positivity and anti-Ro (n=7/20; 35%), anti-dsDNA (n=3/20, 15%), anti-Jo1 (n=3/20, 15%), anti-centromere B (n=2/20; 10%), anti-Scl70 (n=2/20; 10%), anti-RNP/Sm (n=2/20, 10%), anti-Pm/Scl (n=1/20, 5%), and RF (n=13; 65%). Patients were classified as Sjögren’s syndrome (n=7/27, 25.9%), myositis (n=3/27, 11.1%), systemic lupus erythematosus (n=3/27, 11.1%), systemic sclerosis (n=4/27,15.2%), mixed (n=3/27, 11.1%) or undifferentiated connective tissue disease (n=7/27, 25.9%). More than half of anti-Ro52/TRIM21 positive patients presented with interstitial lung fibrosis (18/27, 66.6%), insolated (33.3%) or in association with anti-Jo1 (33.3%). Conclusions. Anti-Ro52/TRIM21 antibodies should be systematically evaluated in patients with SARDs, as antiRo52 positivity (either isolated or in combination with different other ANA specificities) may be associated with definite clinical features. Anti-Ro52/TRIM21 may be useful in identifying a subgroup of patients at risk for developing certain symptoms (particularly interstitial lung disease) of SARDs, with specific therapeutic outcomes.https://rjr.com.ro/articles/2017.3/RJR_2017_3_Art-04.pdfanti-ro52/trim21 antibodiessystemic autoimmune rheumatic disorders |
| spellingShingle | Cristina Pomirleanu Raluca Paiu Georgiana Strugariu Luiza Petrariu Codrina Ancuta CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS Romanian Journal of Rheumatology anti-ro52/trim21 antibodies systemic autoimmune rheumatic disorders |
| title | CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS |
| title_full | CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS |
| title_fullStr | CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS |
| title_full_unstemmed | CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS |
| title_short | CLINICAL SIGNIFICANCE OF ANTI-RO52/TRIM21 ANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISORDERS: PRELIMINARY RESULTS |
| title_sort | clinical significance of anti ro52 trim21 antibodies in systemic autoimmune rheumatic disorders preliminary results |
| topic | anti-ro52/trim21 antibodies systemic autoimmune rheumatic disorders |
| url | https://rjr.com.ro/articles/2017.3/RJR_2017_3_Art-04.pdf |
| work_keys_str_mv | AT cristinapomirleanu clinicalsignificanceofantiro52trim21antibodiesinsystemicautoimmunerheumaticdisorderspreliminaryresults AT ralucapaiu clinicalsignificanceofantiro52trim21antibodiesinsystemicautoimmunerheumaticdisorderspreliminaryresults AT georgianastrugariu clinicalsignificanceofantiro52trim21antibodiesinsystemicautoimmunerheumaticdisorderspreliminaryresults AT luizapetrariu clinicalsignificanceofantiro52trim21antibodiesinsystemicautoimmunerheumaticdisorderspreliminaryresults AT codrinaancuta clinicalsignificanceofantiro52trim21antibodiesinsystemicautoimmunerheumaticdisorderspreliminaryresults |